Blinatumomab and Pembrolizumab |
| |
| Authors: | Emily E. Tabor J. Aubrey Waddell Dominic A. Solimando Jr |
| |
| Affiliation: | *Dr. Tabor is a Pharmacy Practice (PGY1) Resident at Blount Memorial Hospital, Maryville, Tennessee |
| |
| Abstract: | The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: ten.tsacmoc@cvSxRcnO; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: ten.retrahc@ruofddaw.Name: BlinatumomabSynonyms: Blincyto, AMG103, MT-103 |
| |
| Keywords: | |
|
|
